Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia

Int J Oncol. 2003 Sep;23(3):693-6.

Abstract

Methylation profile was analyzed in eleven cases of therapy-related leukemia (t-leukemia) for p14, p15, p16, Rb, hMLH1, hMSH2, MGMT, APC, RAR beta, DAPK, RIZ1, FHIT, and SOCS-1 genes by using methylation specific polymerase chain reaction (MSP) analysis. Six (55%) of eleven cases showed methylation of at least one gene. The average time to the development of t-leukemia after the treatment of the primary tumor was significantly shorter in patients with methylation than those without methylation (49.3 months vs. 133.2 months, P=0.044). These results suggest that hypermethylation might be involved in the development of t-leukemia.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects
  • Bone Marrow Cells / metabolism
  • CpG Islands*
  • DNA Methylation*
  • DNA Repair
  • Disease Progression
  • Female
  • Humans
  • Leukemia / drug therapy*
  • Leukemia / genetics*
  • Leukemia / radiotherapy*
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Promoter Regions, Genetic*
  • Radiotherapy / adverse effects

Substances

  • Antineoplastic Agents